Oncolys BioPharma Inc.

TSE:4588 Stock Report

Market Cap: JP¥24.5b

Oncolys BioPharma Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Yasuo Urata

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure21.7yrs
CEO ownership2.0%
Management average tenureno data
Board average tenure2.7yrs

Recent management updates

Recent updates

Is Oncolys BioPharma (TSE:4588) Using Debt In A Risky Way?

May 29
Is Oncolys BioPharma (TSE:4588) Using Debt In A Risky Way?

Is Oncolys BioPharma (TSE:4588) Using Debt Sensibly?

Dec 20
Is Oncolys BioPharma (TSE:4588) Using Debt Sensibly?

Is Oncolys BioPharma (TSE:4588) A Risky Investment?

Jun 17
Is Oncolys BioPharma (TSE:4588) A Risky Investment?

Health Check: How Prudently Does Oncolys BioPharma (TSE:4588) Use Debt?

Feb 29
Health Check: How Prudently Does Oncolys BioPharma (TSE:4588) Use Debt?

CEO

Yasuo Urata (70 yo)

21.7yrs
Tenure

Mr. Yasuo Urata, M.Sc. has been President and Chief Executive Officer of Oncolys BioPharma Inc. since March 2004. and serves as its Chairman. Mr. Urata served various executive functions at Japan Tobacco p...

Board Members

NamePositionTenureCompensationOwnership
Yasuo Urata
Chairman21.7yrsno data2.01%
¥ 491.4m
Yasunari Kashihara
Managing Director & Director17.7yrsno data0.46%
¥ 113.3m
Toru Saito
Independent Outside Director3.7yrsno datano data
Naoko Iino
Independent Outside Director2.7yrsno datano data
Masaya Nagasue
Outside Auditorless than a yearno datano data
Takahito Yanagisawa
Outside Auditorless than a yearno datano data
Shinichi Kyuse
Full Time Corporate Auditorless than a yearno datano data
2.7yrs
Average Tenure
65yo
Average Age

Experienced Board: 4588's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/10 23:18
End of Day Share Price 2025/11/10 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncolys BioPharma Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kiyokazu YamazakiIchiyoshi Research Institute Inc.